Samsung Bioepis Launches Eylea Biosimilar in Europe, Accelerating Market Push

News|
|
By Lee Yeon-soo
||
[Provided by Samsung Bioepis. Resale and DB prohibited] - Seoul Economic Daily Technology News from South Korea
[Provided by Samsung Bioepis. Resale and DB prohibited]

Samsung Bioepis said Wednesday it has launched Opuviz (aflibercept), a low-concentration formulation (40 mg/mL) ophthalmic treatment, through direct sales in Europe.

Opuviz is a biosimilar of Eylea, developed by U.S.-based Regeneron. The drug treats ophthalmic conditions including wet age-related macular degeneration by binding to vascular endothelial growth factor to inhibit the formation of new blood vessels. Eylea generates global sales of approximately 12 trillion won annually.

The company said it has diversified its ophthalmic portfolio in Europe with the latest launch, following the January release of Byooviz (ranibizumab), a biosimilar of Lucentis. Samsung Bioepis added that it has expanded its lineup of directly sold products in Europe to five since introducing Epysqli (eculizumab), a biosimilar of the rare disease treatment Soliris, in 2023.

A Samsung Bioepis official said the company is steadily expanding the scope of its business operations in Europe.

#SamsungBioepis#Biosimilar#Eylea#Opuviz#Pharma#EuropeMarket#Ophthalmology

Original reporting by Lee Yeon-soo for Seoul Economic Daily.

AI-translated from Korean. Quotes from foreign sources are based on Korean-language reports and may not reflect exact original wording.

View Korean originalTranslation Policy
AI PRISM cover art

🎧Listen to AI PRISM·AI PRISM

Corporate Bonds Hit 4.5%, Record Firms Can't Cover Interest, and Kakao Strikes | June 11 2026

00:0002:29
← Back to Home

AI KEY

Preview
Korean Corporate Intelligence HubKOSPI · KOSDAQ · 12 sectors

A live, cap-weighted view of every KOSPI and KOSDAQ sector, with same-day Korean reporting distilled by company — built for foreign investors, correspondents and analysts who need to scan Korea before the next session.

Open in full screen

Korea Chaebol Tree

Preview
Families Behind the GroupsKFTC May 2026 · DART filings

An English-first interactive map of Samsung, SK, Hyundai, LG and Lotte — built for foreign investors, correspondents and analysts. Korea translates companies into English. We translate the families behind them.

Open in full screen

SIGNAL

Pre-register
English Edition · Capital MarketsM&A · IPO · PE · Fund Flows

Pre-register for SIGNAL English Edition — a premium subscription bringing Korean capital markets coverage (M&A, IPOs, private equity, fund flows) to global institutional investors. First access to the 50% introductory rate.

Open in full screen